Search

Your search keyword '"Shimomura, Tatsuya"' showing total 177 results

Search Constraints

Start Over You searched for: Author "Shimomura, Tatsuya" Remove constraint Author: "Shimomura, Tatsuya"
177 results on '"Shimomura, Tatsuya"'

Search Results

6. Effectiveness and safety of enzalutamide and apalutamide in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC): a multicenter retrospective study

8. Site-Specific Differences of Eligibility for Adjuvant Immunotherapy Among Urothelial Carcinoma Patients Treated With Radical Surgery: Results From a Multicenter Cohort Study

9. Radiographic Progression at Castration-Resistant Prostate Cancer Diagnosis: A Prognostic Indicator of Metastatic Hormone-Sensitive Prostate Cancer

10. Clinical Significance of Intraductal Carcinoma of the Prostate After High-Dose Brachytherapy With External Beam Radiation Therapy: A Single Institution Series and an Updated Meta-Analysis

12. Perioperative renal function change and oncological outcomes of radical nephroureterectomy in patients with upper tract urothelial carcinoma: A multicenter retrospective study

14. Trimodal therapy with high-dose-rate brachytherapy and hypofractionated external beam radiation combined with long-term androgen deprivation for unfavorable-risk prostate cancer

15. Changes in the treatment landscape of metastatic hormone‐sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study.

16. Values of alkaline phosphatase at the diagnosis of castration resistance and response to primary androgen deprivation therapy as predictors of subsequent metastasis in non-metastatic castration-resistant prostate cancer

18. Clinical significance of intraductal carcinoma of the prostate after high-dose brachytherapy with external beam radiation therapy: A single institution series and an updated meta-analysis

19. Patients with PSA below 0.2 ng/mL at 8 years post high‐dose‐rate brachytherapy have an extremely low risk of subsequent recurrence

25. Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer

26. Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high‐risk metastatic hormone‐sensitive prostate cancer

27. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance

29. Reduction of Initial Dose of Enzalutamide does not Decrease the Incidence and Severity of Adverse Events in Castration-Resistant Prostate Cancer

32. Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high‐risk metastatic hormone‐sensitive prostate cancer.

36. Values of alkaline phosphatase at the diagnosis of castration resistance and response to primary androgen deprivation therapy as predictors of subsequent metastasis in non-metastatic castration-resistant prostate cancer

37. The association of PSA levels and survival outcomes in patients with chemotherapy-naïve, castration-resistant prostate cancer (CRPC) who were treated with androgen receptor signaling axis targeting agent (ARAT): A Japanese cohort study.

40. Earlier use of androgen receptor-axis-targeted drugs may improve overall survival in patients with non-metastatic castration-resistant prostate cancer

43. Prospective comparison of the efficacy of caudal versus periprostatic nerve block, both with intrarectal local anesthesia, during transrectal ultrasonography-guided prostatic needle biopsy

44. MP47-13 COMPARISON BETWEEN MID-TERM OUTCOMES OF HIGH-DOSE-RATE BRACHYTHERAPY WITH EXTERNAL-BEAM RADIOTHERAPY COMBINED WITH LONG-TERM ANDROGEN DEPRIVATION THERAPY AND RADICAL PROSTATECTOMY IN PATIENTS WITH HIGH-RISK PROSTATE CANCER.

45. Papillary adenocarcinoma of the prostate: report of 4 cases

48. Bilateral pyeloureteritis cystica: a case report

49. Malignant fibrous histiocytoma of perirenal tissue: a case report

Catalog

Books, media, physical & digital resources